Abstract
Development of SAR in an N-acyl-N'-arylpiperazine series of negative allosteric modulators of mGlu1 using a functional cell-based assay is described in this Letter. Characterization of selected compounds in protein binding assays was used to aid in selecting VU0469650 for further profiling in ancillary pharmacology assays and pharmacokinetic studies. VU0469650 demonstrated an excellent selectivity profile and good exposure in both plasma and brain samples following intraperitoneal dosing in rats.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Allosteric Regulation / drug effects*
-
Animals
-
Central Nervous System / drug effects*
-
Central Nervous System / metabolism
-
Dose-Response Relationship, Drug
-
Molecular Structure
-
Piperazines / chemical synthesis
-
Piperazines / chemistry
-
Piperazines / pharmacology*
-
Rats
-
Receptors, Metabotropic Glutamate / antagonists & inhibitors*
-
Receptors, Metabotropic Glutamate / metabolism
-
Structure-Activity Relationship
Substances
-
Piperazines
-
Receptors, Metabotropic Glutamate
-
VU0469650
-
metabotropic glutamate receptor type 1